Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

Fig. 1

a was adapted from [16], with permission from John Wiley and Sons

Change from baseline in a SBP and b DBP [16, 17]. ABPM ambulatory blood pressure monitoring, CANA canagliflozin, CI confidence interval, DBP diastolic blood pressure, LS least squares, PBO placebo, SBP systolic blood pressure, SE standard error.

Back to article page